

## Inhibition of NF- $\kappa$ B-mediated gene transcription by the human A<sub>2B</sub> adenosine receptor in Chinese hamster ovary cells

Patricia Combes and John M. Dickenson

### Abstract

NF- $\kappa$ B is a transcription factor that plays a vital role in regulating inducible gene expression in immune and inflammatory responses. In view of the well documented effects of adenosine on immune and inflammatory responses, we have explored whether adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors regulate NF- $\kappa$ B activity in transfected Chinese hamster ovary (CHO) cells using a luciferase reporter gene construct. No increases in NF- $\kappa$ B activity were observed in CHO-A<sub>1</sub>, -A<sub>2B</sub> and -A<sub>3</sub> cells stimulated with the non-selective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine. Elevating intracellular cyclic AMP (cAMP) levels using forskolin (direct activator of adenylyl cyclase) and rolipram (type IV, cAMP-specific phosphodiesterase inhibitor), inhibited NF- $\kappa$ B activity in CHO cells. Adenosine A<sub>2B</sub> receptor stimulation also inhibited NF- $\kappa$ B activity, whereas adenosine A<sub>1</sub> and A<sub>3</sub> receptor activation had no effect. These data reflect the known coupling of adenosine A<sub>2B</sub> receptors to increases in cAMP. In conclusion, adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors do not directly activate NF- $\kappa$ B in CHO cells. However, adenosine A<sub>2B</sub> receptor activation significantly inhibited NF- $\kappa$ B activity. Inhibition of NF- $\kappa$ B activity by the adenosine A<sub>2B</sub> receptor may contribute to the anti-inflammatory effects of adenosine.

### Introduction

The purine adenosine regulates a number of physiological functions through the activation of specific cell surface receptors (Ralevic & Burnstock 1998). Four adenosine receptors (A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub>), belonging to the G protein-coupled receptor (GPCR) superfamily, have been cloned and pharmacologically characterized. Adenosine A<sub>2A</sub> and A<sub>2B</sub> receptors are positively coupled to adenylyl cyclase via G<sub>s</sub> proteins, whereas adenosine A<sub>1</sub> and A<sub>3</sub> receptors are negatively coupled to adenylyl cyclase via pertussis toxin-sensitive G<sub>i</sub>/G<sub>o</sub> proteins.

Recent studies have shown that adenosine is a potent regulator of immune and inflammatory responses (Cronstein 1994; Di Virgilio et al 1996). The anti-inflammatory action of adenosine is partially related to its ability to modulate the release of pro-inflammatory cytokines, such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-6 and IL-8 (Bouma et al 1994, 1996; Reinstein et al 1994; McWhinney et al 1996), and attenuate the expression of cell surface adhesion molecules (involved in the development of an inflammatory response) on human endothelial cells (Bouma et al 1996).

The transcription factor NF- $\kappa$ B plays a key role in the regulation of immune and inflammatory responses by modulating gene expression (Barnes & Karin 1997). Inducible genes regulated by NF- $\kappa$ B include pro-inflammatory cytokines, cell

Department of Life Sciences,  
Nottingham Trent University,  
Clifton Lane, Nottingham NG11  
8NS, UK

Patricia Combes, John M.  
Dickenson

**Correspondence:** J. M.  
Dickenson, Department of Life  
Sciences, Nottingham Trent  
University, Clifton Lane, Not-  
tingham NG11 8NS, UK. E-mail:  
john.dickenson@ntu.ac.uk

**Funding:** This work was funded  
by The Royal Society.

adhesion molecules, cell surface inflammatory receptors and inflammatory enzymes, such as inducible cyclooxygenase-2, nitric oxide synthetase and cytosolic phospholipase A<sub>2</sub> (Barnes & Karin 1997).

Recent studies have indicated that GPCRs are capable of regulating NF- $\kappa$ B activity (Cowen et al 1997; Kranzhöfer et al 1999; Xie et al 2000). Therefore, the aim of the present study was to investigate whether adenosine receptor subtypes regulate NF- $\kappa$ B activity in Chinese hamster ovary (CHO) cells expressing adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors, together with a NF- $\kappa$ B-dependent luciferase reporter gene plasmid.

## Materials and Methods

### Materials

5'-*N*-ethylcarboxamidoadenosine (NECA) was obtained from Sigma Chemical Co. (Poole, Dorset, UK). Forskolin and rolipram were from Calbiochem (Nottingham, UK). Dulbecco's modified Eagle's medium (DMEM)/nutrient mix F-12 (1:1) and fetal calf serum (FCS) were from Sigma Chemical Co. All other chemicals were of analytical grade.

### Cell culture

CHO cells transfected with the human A<sub>1</sub> adenosine receptor (CHO-A<sub>1</sub>) were a generous gift from Dr Andrea Townsend-Nicholson and Professor John Shine (Garvan Institute, Sydney, Australia). CHO cells transfected with the human adenosine A<sub>2B</sub> and A<sub>3</sub> receptors (CHO-A<sub>2B</sub> and CHO-A<sub>3</sub>, respectively) were kindly provided by Professor Klotz (Klotz et al 1998). Cells were cultured in DMEM/nutrient mix F-12 (1:1) supplemented with 2 mM L-glutamine and 10% (v/v) FCS. Cells were maintained at 37°C in a humidified 5% CO<sub>2</sub> atmosphere and subcultured (1:10 split ratio) using trypsin (0.05%, w/v)/EDTA (0.02%, w/v).

### NF- $\kappa$ B-dependent luciferase measurements

CHO-A<sub>1</sub>, -A<sub>2B</sub> and -A<sub>3</sub> cells were stably transfected with a NF- $\kappa$ B-dependent luciferase reporter plasmid (pkBtkluc) containing three copies of an NF- $\kappa$ B binding site from the immunoglobulin  $\kappa$  light chain (a gift from Professor Takemori; see Kashiwada et al 1998). CHO-A<sub>1</sub>, -A<sub>2B</sub> and -A<sub>3</sub> cells were co-transfected with pkBtkluc and pZEOSV (Invitrogen) and then selected and maintained using 500  $\mu$ g mL<sup>-1</sup> G418 and 250  $\mu$ g mL<sup>-1</sup> zeocin (Invitrogen). Cells were grown in 24-well plate cluster dishes, and when 80–90% confluent were washed once

with serum-free DMEM/F-12 medium before incubating for 24 h in serum-free DMEM/F-12 medium (1 mL/well). Serum-starved cells were stimulated with appropriate agents for 6 h and then washed twice with Dulbecco's phosphate-buffered saline solution (Sigma Chemical Co.) before the addition of 120  $\mu$ L culture lysis reagent (Promega). After shaking for 15 min, the cell lysates were removed and placed into Eppendorf microcentrifuge tubes and vortexed. Cell lysates (20  $\mu$ L) were then transferred to opaque 96-well plates and luminescence measured using a Dynex Microtiter Plate Luminometer. The luminometer injects 100  $\mu$ L luciferase assay substrate (Promega) into each sample and determines luminescence over 10 s.

### Data analysis

Statistical significance was determined by analysis of variance followed by Dunnett's multiple comparison tests using the computer program Prism (GraphPAD) and  $P < 0.05$  was considered statistically significant. All data are presented as mean  $\pm$  s.e.m., where n refers to the number of separate experiments.

## Results

### Potential activation of NF- $\kappa$ B activity by adenosine receptor subtypes

The potential regulation of NF- $\kappa$ B-mediated transcriptional activity by human adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors was explored in CHO cells using an NF- $\kappa$ B luciferase reporter construct. Stimulation of serum-starved CHO cells (expressing adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors) with 10% FCS produced a robust increase in luciferase activity, confirming expression of the NF- $\kappa$ B reporter gene in these cells. However, treatment of CHO-A<sub>1</sub>, -A<sub>2B</sub> and -A<sub>3</sub> cells with the non-selective adenosine receptor agonist NECA (10  $\mu$ M) did not increase luciferase expression (Table 1). These data indicate that adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors do not directly activate NF- $\kappa$ B in transfected CHO cells.

### Inhibition of NF- $\kappa$ B activity by the adenosine A<sub>2B</sub> receptor

Elevated levels of cyclic AMP (cAMP) are known to inhibit the activation of NF- $\kappa$ B (see Haraguchi et al 1995). In this study, we investigated the effects of elevating intracellular cAMP levels using forskolin (direct activator of adenylyl cyclase) and rolipram (type IV,

**Table 1** Potential regulation of NF- $\kappa$ B after adenosine A<sub>1</sub>, A<sub>2B</sub>, A<sub>3</sub> receptor activation in Chinese hamster ovary (CHO) cells.

Treatment	% Response to FCS		
	CHO-A <sub>1</sub>	CHO-A <sub>2B</sub>	CHO-A <sub>3</sub>
10% FCS	100	100	100
Basal	14 ± 2	14 ± 3	19 ± 2
NECA	16 ± 2	15 ± 2	16 ± 2

CHO-A<sub>1</sub>, -A<sub>2B</sub> and -A<sub>3</sub> cells transfected with the NF- $\kappa$ B-dependent luciferase reporter plasmid were serum-starved for 24 h before stimulation for 6 h with 10% fetal calf serum (FCS) or the non-selective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA; 10  $\mu$ M). The data are expressed as a percentage of the response to 10% FCS (= 100%) and represent the mean  $\pm$  s.e.m. of four independent experiments each measured in triplicate. No significant changes in luciferase activity were observed after treatment of cells with NECA.

cAMP-specific phosphodiesterase inhibitor) on NF- $\kappa$ B activity in CHO cells. As summarized in Table 2, forskolin (10  $\mu$ M) and rolipram (10  $\mu$ M) significantly reduced FCS-induced increases in NF- $\kappa$ B activation in CHO-A<sub>2B</sub> cells. Treating CHO-A<sub>2B</sub> cells with both forskolin and rolipram produced a similar degree of inhibition of FCS-induced increases in NF- $\kappa$ B as observed for forskolin alone (Table 2). Similar results were also obtained using CHO-A<sub>1</sub> and CHO-A<sub>3</sub> cells (data not shown). Having established that increases in intracellular cAMP levels can regulate NF- $\kappa$ B activity, we then examined whether adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptor stimulation modulates FCS-induced NF- $\kappa$ B activation. Stimulating CHO-A<sub>1</sub> and -A<sub>3</sub> cells with NECA (10  $\mu$ M) had no significant effect on FCS-induced increases in luciferase activity (data not shown). This presumably reflects the negative coupling of adenosine A<sub>1</sub> and A<sub>3</sub> receptors to adenylyl cyclase via G<sub>i</sub> proteins. However, stimulating CHO-A<sub>2B</sub> cells with NECA (10  $\mu$ M) produced a significant inhibition of FCS-induced NF- $\kappa$ B activation (summarized in Table 2). Treatment of CHO-A<sub>2B</sub> cells with NECA (10  $\mu$ M) in the presence of rolipram (10  $\mu$ M), further inhibited FCS-induced increases in NF- $\kappa$ B activation (Table 2). These observations indicate that the G<sub>s</sub> protein-coupled adenosine A<sub>2B</sub> receptor is capable of modulating NF- $\kappa$ B transcriptional activity in CHO cells.

## Discussion

Previous studies have shown that adenosine can inhibit pro-inflammatory cytokine release (TNF- $\alpha$ , IL-6 and

**Table 2** Effect of forskolin, rolipram and 5'-N-ethylcarboxamidoadenosine (NECA) on NF- $\kappa$ B-mediated luciferase expression in CHO-A<sub>2B</sub> cells.

Treatment	% Inhibition of response to FCS
Forskolin	60 ± 4*
Rolipram	23 ± 3*
Forskolin and rolipram	56 ± 6*
NECA	46 ± 7*
NECA and rolipram	60 ± 3*

CHO-A<sub>2B</sub> cells transfected with the NF- $\kappa$ B-dependent luciferase reporter plasmid were serum-starved for 24 h before stimulation for 6 h with 10% fetal calf serum (FCS) alone or in the presence of forskolin (10  $\mu$ M), rolipram (10  $\mu$ M) or the non-selective adenosine receptor agonist NECA (10  $\mu$ M). The effects of forskolin and NECA were also investigated in the presence of rolipram (10  $\mu$ M). The data are expressed as the percentage inhibition of the response obtained with 10% FCS alone (after subtracting the appropriate basal value). Data represent the mean  $\pm$  s.e.m. of four independent experiments each measured in triplicate. No significant changes in basal luciferase activity were observed after treatment with rolipram or forskolin. \**P* < 0.05, significantly different compared with the response obtained with 10% FCS alone.

IL-8) and the expression of cell surface adhesion molecules (Bouma et al 1994, 1996; Reinstein et al 1994; McWhinney et al 1996). In this study, we used an NF- $\kappa$ B luciferase reporter gene construct to determine whether the adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptor subtypes regulate NF- $\kappa$ B activity in transfected CHO cells, given that the well documented effects of adenosine on immune and inflammatory responses may involve regulation of NF- $\kappa$ B activity. We found that stimulation of adenosine A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptor subtypes had no significant effect on NF- $\kappa$ B activity in transfected CHO cells. Interestingly, the G<sub>i</sub> protein-coupled 5-HT<sub>1A</sub> receptor activates NF- $\kappa$ B in CHO cells (Cowen et al 1997). The inability of adenosine A<sub>1</sub> and A<sub>3</sub> receptors (both G<sub>i</sub> protein-linked) to directly stimulate NF- $\kappa$ B activity may be a consequence of receptor number. In the study of Cowen et al (1997) the 5-HT<sub>1A</sub> receptor was expressed at 2.8 pmol mg<sup>-1</sup> of protein, whereas in this study the adenosine A<sub>1</sub> receptor and adenosine A<sub>3</sub> receptor were expressed at approximately 1000 and 800 fmol mg<sup>-1</sup> of protein, respectively (Klotz et al 1998). Alternatively, and in view of the high level of receptor expression, NF- $\kappa$ B activation by the 5-HT<sub>1A</sub> receptor in CHO cells may reflect coupling of the 5-HT<sub>1A</sub> receptor to other types of G proteins, for example G<sub>q</sub>. Indeed, reports published to date describing GPCR coupling to NF- $\kappa$ B mainly involve G<sub>q</sub> protein-coupled receptors, for ex-

ample muscarinic M3 receptors, bradykinin B<sub>2</sub> receptors and  $\alpha_{1A}$ -adrenergic receptors (Todisco et al 1999; Minneman et al 2000; Xie et al 2000).

Previous studies have shown that NF- $\kappa$ B activity can be inhibited by increases in intracellular cAMP levels (see Haraguchi et al 1995). In this study we have shown that treatment of CHO cells with agents that elevate intracellular cAMP levels (independent of receptor activation) are capable of inhibiting NF- $\kappa$ B activity. Furthermore, adenosine A<sub>2B</sub> receptor activation also significantly inhibits NF- $\kappa$ B activity (induced by FCS) in CHO cells. This presumably reflects the coupling of the adenosine A<sub>2B</sub> receptor in CHO cells to increases in intracellular cAMP (Klotz et al 1998). In contrast, activation of the G<sub>i</sub> protein-coupled adenosine A<sub>1</sub> and A<sub>3</sub> receptors did not inhibit (or potentiate) NF- $\kappa$ B activity in CHO cells. It is interesting to note that Schwaninger et al (1997) reported that the adenosine A<sub>2B</sub> receptor increased IL-6 gene expression via NF- $\kappa$ B activation in primary astrocytes. The ability of the adenosine A<sub>2B</sub> receptor to activate NF- $\kappa$ B in astrocytes (compared with the inhibition observed in this study using CHO cells) may reflect cell-specific differences in adenosine A<sub>2B</sub> receptor-mediated cell signalling. The adenosine A<sub>2B</sub> receptor has been reported to activate phospholipase C (indicative of coupling to G<sub>q</sub> protein) in rat astrocytes, and this may explain NF- $\kappa$ B activation by the adenosine A<sub>2B</sub> receptor in astrocytes (Pilitsis & Kimelberg 1998). However, it is not known whether the adenosine A<sub>2B</sub> receptor couples to phospholipase C in transfected CHO cells.

In conclusion, this study has shown that transfected human A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors do not directly activate NF- $\kappa$ B in CHO cells. We have shown for the first time that stimulation of the adenosine A<sub>2B</sub> receptor inhibits NF- $\kappa$ B-mediated gene transcription (adenosine A<sub>1</sub> and A<sub>3</sub> receptors had no effect), presumably via a cAMP-dependent pathway in CHO cells. However, further studies are required to investigate the potential regulation of NF- $\kappa$ B by adenosine receptor subtypes in physiological relevant cell types.

## References

- Barnes, P. J., Karin, M. (1997) Mechanisms of disease – nuclear factor kappaB – a pivotal transcription factor in chronic inflammatory diseases. *N. Engl. J. Med.* **336**: 1066–1071
- Bouma, M. G., Stad, R. K., Van den Wildenberg, F. A. J. M., Buurman, W. A. (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. *J. Immunol.* **153**: 389–396
- Bouma, M. G., Van den Wildenberg, F. A. J. M., Buurman, W. A. (1996) Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. *Am. J. Physiol.* **270**: C522–C529
- Cowen, D. S., Molinoff, P. B., Manning, D. R. (1997) 5-Hydroxytryptamine<sub>1A</sub> receptor-mediated increases in receptor expression and activation of nuclear factor- $\kappa$ B in transfected Chinese hamster ovary cells. *Mol. Pharmacol.* **52**: 221–226
- Cronstein, B. N. (1994) Adenosine, an endogenous anti-inflammatory agent. *J. Appl. Physiol.* **76**: 5–13
- Di Virgilio, F., Ferrari, D., Chiozzi, P., Falzoni, S., Szanz J. M., Dal Susino, M., Mutini, C., Hanau, S., Baricordi, O. R. (1996) Purinoceptor function in the immune system. *Drug Dev. Res.* **39**: 319–329
- Haraguchi, S., Good, R. A., Day, N. K. (1995) Immunosuppressive retroviral peptides: cAMP and cytokine patterns. *Immunol. Today* **16**: 595–603
- Kashiwada, M., Shirakata, Y., Inoue, J.-I., Nakano, H., Okazaki, K., Okumura, K., Yamamoto, T., Nagaoka, H., Takemori, T. (1998) Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway. *J. Exp. Med.* **187**: 237–244
- Klotz, K. N., Hessling, J., Hegler, J., Owman, C., Kull, B., Fredholm, B. B., Lohse, M. J. (1998) Comparative pharmacology of human adenosine receptor subtypes – characterisation of stably transfected receptors in CHO cells. *Naunyn Schmiedebergs Arch. Pharmacol.* **357**: 1–9
- Kranzhöfer, R., Browatzki, M., Schmidt, J., Kubler W. (1999) Angiotensin II activates the proinflammatory transcription nuclear factor- $\kappa$ B in human monocytes. *Biochem. Biophys. Res. Commun.* **257**: 826–828
- McWhinney, C. D., Dudley, M. W., Bowlin, T. L., Peet, N. P., Schook, L., Bradshaw, M., De, M., Borchering, D. R., Edwards, C. K. III (1996) Activation of adenosine A<sub>3</sub> receptors on macrophages inhibits tumor necrosis factor- $\alpha$ . *Eur. J. Pharmacol.* **310**: 209–216
- Minneman, K. P., Lee, D., Zhong, H., Berts, A., Abbott, K. L., Murphy, T. J. (2000) Transcriptional responses to growth factor and G-protein coupled receptors in PC12 cells: comparison of  $\alpha_1$ -adrenergic subtypes. *J. Neurochem.* **74**: 2392–2400
- Pilitsis, J. G., Kimelberg, H. K. (1998) Adenosine receptor mediated stimulation of intracellular calcium in acutely isolated astrocytes. *Brain Res.* **798**: 294–303
- Ralevic, V., Burnstock, G. (1998) Receptors for purines and pyrimidines. *Pharmacol. Rev.* **50**: 413–492
- Reinstein, L. J., Lichtman, S. N., Currin, R. T., Wang, J., Thurman, R. G., Lemasters, J. J. (1994) Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A<sub>2</sub> receptors on rat Kupffer cells. *Hepatology* **19**: 1445–1452
- Schwanger, M., Neher, M., Viegas, E., Schneider, A., Spranger, M. (1997) Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. *J. Neurochem.* **69**: 1145–1150
- Todisco, A., Ramamoorthy, S., Pausawasdi, N., Tacey, K. (1999) Carbachol activates I $\kappa$ B kinase in isolated canine gastric parietal cells. *Biochem. Biophys. Res. Commun.* **261**: 877–884
- Xie, P., Browning, D. D., Hay, N., Mackman, Ye, R. D. (2000) Activation of NF- $\kappa$ B by bradykinin through a G $\alpha_q$ - and G $\beta\gamma$ -dependent pathway that involves phosphoinositide 3-kinase and Akt. *J. Biol. Chem.* **275**: 24 907–24 914